{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:45:00Z","timestamp":1793727900256,"version":"4.6.1"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T00:00:00Z","timestamp":1756598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are novel therapeutic agents for managing anemia in patients with chronic kidney disease (CKD); however, no clinically viable markers for the anemia-improving effect of HIF-PHI have been reported. Therefore, we evaluated changes in iron metabolism markers and identified predictors of anemia amelioration during HIF-PHi treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included 48 patients with CKD not undergoing dialysis: 29 patients receiving epoetin \u03b2-pegol, an erythropoiesis-stimulating agent (ESA) and 19 patients receiving roxadustat, an HIF-PHi. Markers of iron metabolism, including hepcidin, were measured during treatments using a widely available automated analyzer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The hemoglobin levels did not differ substantially between the HIF-PHi and ESA groups. Patients treated with HIF-PHI exhibited lower serum iron, ferritin, transferrin saturation, and hepcidin values and higher unsaturated iron-binding capacity at 1 month than did patients receiving the ESA. Reduced hepcidin levels at 1 month were strongly associated with increased hemoglobin levels at 3 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Our findings suggest that the hepcidin level, as an initial response, can help predict the responsiveness of the HIF-PHi to anemia in patients with CKD. Measuring hepcidin, an integral indicator of iron metabolism, using standard equipment in general hospital laboratories would be beneficial in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/labmed\/lmaf005","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T07:31:39Z","timestamp":1744270299000},"page":"608-613","source":"Crossref","is-referenced-by-count":4,"title":["Hepcidin values can help predict the responsiveness of roxadustat for treating anemia in patients with chronic kidney disease"],"prefix":"10.1093","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5648-5559","authenticated-orcid":false,"given":"Tatsuya","family":"Murata","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory Science, Faculty of Health Sciences, Yamaguchi University Graduate School of Medicine , Ube, Yamaguchi ,","place":["Japan"]},{"name":"Clinical Research Laboratory, JA Hiroshima General Hospital , 1-3-3 Jigozenchou, Hatsukaichi, Hiroshima 738-8503 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhito","family":"Fukuoka","sequence":"additional","affiliation":[{"name":"Clinical Research Laboratory, JA Hiroshima General Hospital , 1-3-3 Jigozenchou, Hatsukaichi, Hiroshima 738-8503 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Fujii","sequence":"additional","affiliation":[{"name":"Clinical Research Laboratory, JA Hiroshima General Hospital , 1-3-3 Jigozenchou, Hatsukaichi, Hiroshima 738-8503 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6838-3456","authenticated-orcid":false,"given":"Toshiaki","family":"Yujiri","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Science, Faculty of Health Sciences, Yamaguchi University Graduate School of Medicine , Ube, Yamaguchi ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,31]]},"reference":[{"key":"2025112208222990300_CIT0001","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.34067\/KID.0001442022","article-title":"Changes in iron availability with roxadustat in nondialysis- and dialysis-dependent patients with anemia of CKD","volume":"3","author":"Pergola","year":"2022","journal-title":"Kidney360"},{"key":"2025112208222990300_CIT0002","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD","volume":"23","author":"Babitt","year":"2012","journal-title":"J Am Soc Nephrol."},{"key":"2025112208222990300_CIT0003","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/bjh.12311","article-title":"Guideline for the laboratory diagnosis of functional iron deficiency","volume":"161","author":"Thomas","year":"2013","journal-title":"Br J Haematol."},{"key":"2025112208222990300_CIT0004","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1681\/ASN.2019020213","article-title":"Iron deficiency in chronic kidney disease: updates on pathophysiology, diagnosis, and treatment","volume":"31","author":"Batchelor","year":"2020","journal-title":"J Am Soc Nephrol."},{"key":"2025112208222990300_CIT0005","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1146\/annurev-med-043021-032816","article-title":"Hepcidin and iron in health and disease","volume":"74","author":"Nemeth","year":"2023","journal-title":"Annu Rev Med."},{"key":"2025112208222990300_CIT0006","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.2215\/CJN.08161109","article-title":"Reduction of serum hepcidin by hemodialysis in pediatric and adult patients","volume":"5","author":"Zaritsky","year":"2010","journal-title":"Clin J Am Soc Nephrol."},{"key":"2025112208222990300_CIT0007","doi-asserted-by":"publisher","first-page":"e13896","DOI":"10.1016\/j.heliyon.2023.e13896","article-title":"Comparison between liquid chromatography\/tandem mass spectroscopy and a novel latex agglutination method for measurement of hepcidin-25 concentrations in dialysis patients with renal anemia: a multicenter study","volume":"9","author":"Kamei","year":"2023","journal-title":"Heliyon"},{"key":"2025112208222990300_CIT0008","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.ekir.2021.04.003","article-title":"Phase 3 study of roxadustat to treat anemia in non-dialysis-dependent CKD","volume":"6","author":"Akizawa","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2025112208222990300_CIT0009","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s10157-022-02225-w","article-title":"Clinical parameters among patients in Japan with anemia and non-dialysis-dependent chronic kidney disease with and without diabetes mellitus who received roxadustat","volume":"26","author":"Akizawa","year":"2022","journal-title":"Clin Exp Nephrol."},{"key":"2025112208222990300_CIT0010","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.3390\/jcm12134217","article-title":"Iron parameters in patients treated with roxadustat for anemia of chronic kidney disease","volume":"12","author":"Ganz","year":"2023","journal-title":"J Clin Med"},{"key":"2025112208222990300_CIT0011","doi-asserted-by":"publisher","first-page":"e33558","DOI":"10.1097\/MD.0000000000033558","article-title":"The association of hepcidin, reticulocyte hemoglobin equivalent and anemia-related indicators on anemia in chronic kidney disease","volume":"102","author":"Gao","year":"2023","journal-title":"Medicine (Baltimore)."},{"key":"2025112208222990300_CIT0012","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.htct.2021.05.006","article-title":"Evaluation of RET-He as an early indicator of iron deficiency anemia in pregnant women","volume":"45","author":"B\u00f3","year":"2023","journal-title":"Hematol Transfus Cell Ther"},{"key":"2025112208222990300_CIT0013","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1365-2257.2006.00812.x","article-title":"Reticulocyte hemoglobin equivalent (Ret He) and assessment of iron-deficient states","volume":"28","author":"Brugnara","year":"2006","journal-title":"Clin Lab Haematol."},{"key":"2025112208222990300_CIT0014","doi-asserted-by":"publisher","first-page":"128","DOI":"10.5005\/jp-journals-10018-1410","article-title":"Reticulocyte hemoglobin equivalent (Ret-He) as a potential diagnostic marker of iron deficiency anemia among Bangladeshi adults","volume":"13","author":"Miah","year":"2023","journal-title":"Euroasian J Hepatogastroenterol"},{"key":"2025112208222990300_CIT0015","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","article-title":"Roxadustat for anemia in patients with kidney disease not receiving dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med."},{"key":"2025112208222990300_CIT0016","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1053\/j.ajkd.2016.12.011","article-title":"Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD","volume":"69","author":"Gupta","year":"2017","journal-title":"Am J Kidney Dis."},{"key":"2025112208222990300_CIT0017","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","article-title":"Roxadustat treatment for anemia in patients undergoing long-term dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med."},{"key":"2025112208222990300_CIT0018","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1182\/blood-2007-07-100677","article-title":"Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis","volume":"111","author":"Silvestri","year":"2008","journal-title":"Blood."},{"key":"2025112208222990300_CIT0019","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1532\/LH96.06037","article-title":"Reticulocyte hemoglobin equivalent: an indicator of reduced iron availability in chronic kidney diseases during erythropoietin therapy","volume":"13","author":"Garzia","year":"2007","journal-title":"Lab Hematol."},{"key":"2025112208222990300_CIT0020","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/j.1751-553X.2009.01179.x","article-title":"Usefulness of measuring reticulocyte hemoglobin equivalent in the management of haemodialysis patients with iron deficiency","volume":"32","author":"Miwa","year":"2010","journal-title":"Int J Lab Hematol."},{"key":"2025112208222990300_CIT0021","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.4103\/1319-2442.308335","article-title":"Diagnosis of iron deficiency in hemodialysis patients: usefulness of measuring reticulocyte hemoglobin equivalent","volume":"31","author":"Sany","year":"2020","journal-title":"Saudi J Kidney Dis Transpl."},{"key":"2025112208222990300_CIT0022","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1681\/ASN.2020091311","article-title":"Phase 3 randomized study comparing vadadustat with darbepoetin alfa for anemia in Japanese patients with nondialysis-dependent CKD","volume":"32","author":"Nangaku","year":"2021","journal-title":"J Am Soc Nephrol."},{"key":"2025112208222990300_CIT0023","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/nep.13835","article-title":"Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF-PH inhibitors","volume":"26","author":"Yap","year":"2021","journal-title":"Nephrology (Carlton)"}],"container-title":["Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/56\/6\/608\/64169634\/lmaf005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/56\/6\/608\/64169634\/lmaf005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T13:22:34Z","timestamp":1763817754000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/labmed\/article\/56\/6\/608\/8244928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,31]]},"references-count":23,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,8,31]]},"published-print":{"date-parts":[[2025,11,22]]}},"URL":"https:\/\/doi.org\/10.1093\/labmed\/lmaf005","relation":{},"ISSN":["0007-5027","1943-7730"],"issn-type":[{"value":"0007-5027","type":"print"},{"value":"1943-7730","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,8,31]]}}}